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In one geographical area, 14 high-risk human papillomavirus types in cervical intraepithelial neoplasia (CIN2/3; n¼139) and cervical
squamous cell carcinoma (SCC; n¼84) were analysed. HPV18 was more prevalent in SCC than CIN2/3 (OR 9.8; 95% confidence
interval: 2.5–39). Other high-risk types prevalences corresponded in CIN2/3 and SCC. Evaluations using CIN2/3 as a measure of
efficiency underestimate the contribution of HPV18 to SCC.
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Human papillomavirus (HPV) infections are the cause of cervical
cancer and its precursors lesions (Walboomers et al, 1999). So far,
15 HPV types have been classified as high-risk types, and three
types have been classified as probable high risk (Munoz et al,
2003). Within the group of high-risk HPV (hrHPV) types, different
types seem to confer different degrees of risk for cervical cancer
and its precursor lesions (Clifford et al, 2006). A markedly
increased risk of cervical cancer has been attributed to HPV16 and
HPV18, as prevalence studies have shown that 60–70% of cervical
squamous cell carcinoma (SCC) cases are positive for HPV16 or
HPV18 (Munoz et al, 2003).
As a consequence, assessment of the additive value of HPV
typing in cervical screening is the subject of many ongoing studies.
However, screening evaluations generally use high-grade cervical
intraepithelial neoplasia (CIN2/3) as intermediate end point of
cervical cancer. This may lead to underestimation or overestima-
tion of the contribution of certain HPV types in case the HPV type
distribution between CIN2/3 and cervical cancer differs. Indeed,
several studies suggest that HPV18 is underrepresented in CIN2/3
compared to SCC (Bulkmans et al, 2005; Castle et al, 2005; Khan
et al, 2005), and in a meta-analysis as well (Clifford et al, 2006).
Here, we address type distribution of different hrHPV types in
CIN2/3 and SCC samples collected in one geographical area.
MATERIALS AND METHODS
Study selection
From the archives of the Department of pathology of Ziekenhuis
Walcheren in The Netherlands, we identified 187 specimens of
CIN2/3 (87 CIN2 and 100 CIN3) diagnosed after screening between
1996 and 2000, and 90 specimens of SCC from the period 1981
to 1998. The department of pathology serves the population of
the Walcheren peninsula, where follow-up of screened women is
approximately 90% complete. All histological samples were
collected retrospectively and were subjected to revision. The
Medical Ethics Committee of VU University Medical Center
approved the study (2001/179).
HPV testing
Representative samples of the formalin-fixed biopsies were
processed for PCR analysis (Walboomers et al, 1999; Jacobs
et al, 2000). Amplification of a 209 base-pair fragment of the
b-globin gene was performed to test the integrity of DNA (Roda
Husman et al, 1994). Detection of hrHPV was performed by GP
5þ/6þ consensus primer PCR enzyme immunoassay, using a
cocktail of 21 low-risk types and 14 high-risk types. All HPV-
positive samples were typed by reverse line blotting (van den Brule
et al, 2002). We tested for hrHPV16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, and 68 and lrHPV6, 11, 32, 40, 42, 43, 44, 54, 55, 57,
61, 70, 71, 72, 81, 83, 84, 85, 86, cp6108 and jc9710 (Jacobs et al,
1997). In addition, all GP5þ/6þ PCR-negative samples were
evaluated by E7 region type-specific PCR for the same 14 high-risk
types to exclude the presence of hrHPV in integrated form and/or
loss of the GP5þ/6þ primer-binding region (Walboomers et al,
1999). Technicians performing PCR analysis were blinded for
histological classification of samples.
Study material
Formalin-fixed archival material could not be retrieved for 17
cases with CIN2/3. Of the women with CIN2/3, 21 samples tested
HPV-negative and in seven cases, only low-risk types could be
identified. One case tested hrHPV-positive without identifying a
specific high-risk type, leaving 139 cases of CIN2/3 with known
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shrHPV type for statistical analysis. Of the women with SCC, seven
cases tested negative for HPV by both assays, leaving 83 cases with
SCC and a known hrHPV type for statistical analysis.
Statistical analysis
Differences in prevalence of hrHPV types for CIN2/3 compared to
SCC were examined using the Mantel-Haenszel common odds
ratio (ORMH) and 95% confidence intervals (95% CIs). Statistical
significance was tested by Cochran’s Mantel-Haenszel test. Data
were stratified by age (i.e., below 29 years, 29–33, 34–38, 39–43,
44–48, 49–53, 54–58, 59–61 and 62 years and over) and whether
infections were single or multiple. The presence of an association
between ORMH and age was tested by Breslow–Day’s test of
homogeneity. Analyses were repeated for women with single
infections only.
The presented results may not be free of hidden bias as there is
some evidence that HPV18-positive lesions are underrated by
cytology (Woodman et al, 2003; Berkhof et al, 2006). Therefore, it
cannot be excluded that prevalence differences of certain hrHPV
types in CIN2/3 compared to SCC is associated with cytological
screening failures. We examined the influence of hidden bias by
computing an adjusted P-value obtained under the assumption
that among the hrHPV-positive CIN2/3 and SCC cases, the odds of
observing a certain hrHPV type in SCC compared to CIN2/3
differed by a factor 2 (Rosenbaum (1991).
RESULTS
The mean age of women with CIN2/3 (n¼139) was 37 years (range
26–57 years). Women with SCC (n¼84) had a mean age of 49
years (range 27–88 years). The mean age of women with SCC was
higher than the mean age of women with CIN2/3 (Po0.001).
Multiple HPV infections were present in 9.4% (13 out of 139) of
CIN2/3, and in 10.8% (9 out of 83) of SCC (P¼0.719).
Table 1 displays the hrHPV type-specific prevalence rates in
women with CIN2/3 compared to SCC. In women with CIN2/3,
59.7% of hrHPV positivity was due to HPV16 and 12.9% to HPV31.
Another 2.9% of hrHPV infections were HPV18 and 11.5% HPV52
positive. In women with SCC, 69.9% of hrHPV positivity was due
to HPV16. HPV31 was present in 7.2% of cases, and HPV18 in
12.0%. No SCC cases tested positive for HPV52 in this study. Type-
specific prevalences did not substantially change when analysing
women with single infections separately.
Women having SCC carried HPV16 more often than women
with CIN2/3, although the estimated ORMH was not statistically
significant (ORMH 1.5; 95% CI: 0.8–3.1). The prevalence of HPV18
was significantly higher in SCC than in CIN2/3 (ORMH 8.3; 95% CI:
1.9–36). The other high-risk HPV types were not associated with
increased risks individually, but when all hrHPV-positive infec-
tions without HPV16 and HPV18 were analysed as one group, the
result was significant (ORMH 0.4; 95% CI: 0.2–0.8). For none of the
HPV types OR varied with age (data not shown). Results for single
infections were comparable.
Even when assuming that the odds to detect an HPV18-
associated SCC compared to an HPV18-associated CIN2/3 differed
by a factor 2, HPV18 would still be increased in SCC compared to
CIN2/3 (P¼0.035).
DISCUSSION
In this cross-sectional study, we compared hrHPV type-specific
prevalence in CIN2/3 and invasive carcinomas in women identified
through population-based cervical screening in a geographically
restricted area. We demonstrated that HPV18 prevalence is
increased in SCC compared to premalignant lesions. In addition,
this study underlines the previously recognised importance of
HPV16 for the development of SCC. Other types did not show a
prevalence difference.
The increased prevalence of HPV18 in cervical cancer compared
to CIN2/3 as found in our study is in agreement with a recent
meta-analysis and data from Australia, South Africa and the US
(Clifford et al, 2003; Kay et al, 2003; Zuna et al, 2004). The sample
size of our study was slightly low, because CIN2/3 and SCC cases
were collected from one restricted geographical area. Nonetheless,
we were able to demonstrate effects of HPV18 in SCC. Our study
cannot differentiate between increased progression risks of HPV18
for the transition of CIN2/3 to SCC as an explanation of our
findings, and underdetection of screen-diagnosed CIN2/3 lesions
associated with HPV18 as an alternative theory. Our previous,




SCC CIN2/3 SCCB4CIN2/3 SCC CIN2/3 SCCB4CIN2/3
n¼84 n¼139 n¼74 n¼126
Type N (%) N (%) OR (95% CI) PN (%) N (%) OR (95% CI) P
16 58 (69.9) 83 (59.7) 1.5 (0.8–3.1) 0.229 55 (74.3) 75 (59.5) 2.1 (1.0–4.5) 0.065
18 10 (12.0) 4 (2.9) 8.3 (1.9–36) 0.002 8 (10.8) 3 (2.4) 10 (2.0–52) 0.005
n16/n18 17 (20.5) 51 (36.7) 0.4 (0.2–0.8) 0.009 11 (14.9) 47 (37.3) 0.2 (0.1–0.5) 0.001
31 6 (7.2) 18 (12.9) 0.4 (0.1–1.5) 0.145 3 (4.1) 11 (8.7) 0.5 (0.1–2.1) 0.371
33 3 (3.6) 8 (5.8) 1.0 (0.2–4.6) 0.959 1 (1.4) 7 (5.6) 0.4 (0.1–3.4) 0.390
35 2 (2.4) 5 (3.6) 0.2 (0.1–3.3) 0.272 — 3 (2.4) — —
39 4 (4.8) — — — 1 (1.4) — — —
45 5 (6.0) 6 (4.3) 0.8 (0.1–6.1) 0.850 4 (5.4) 3 (2.4) 0.6 (0.1–8.1) 0.701
51 — 4 (2.9) — — — 3 (2.4) — —
52 — 16 (11.5) — — — 14 (11.1) — —
56 2 (2.4) 1 (0.7) 1.6 (0.1–46) 0.815 1 (1.4) 1 (0.8) 1.7 (0.1–28) 0.705
58 2 (2.4) 7 (5.0) 1.6 (0.1–11) 0.652 1 (1.4) 4 (3.2) 0.6 (0.1–9.0) 0.738
59 — 1 (0.7) — — — 1 (0.8) — —
66 — 1 (0.7) — — — — — —
68 — — — — — — — —
CIN2/3¼cervical intraepithelial neoplasia; HrHPV¼high-risk human papillomavirus; SCC, squamous cell carcinoma. Bold typeface indicates Po0.05.
aAnalyses are adjusted for
age in 5-year strata.
bMultiple and single infections combined. Analyses are adjusted for multiplicity of infection.
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scross-sectional study indicated a preferential risk of HPV18 for the
development of cancer from normal cytology (Bulk et al, 2006).
However, the estimate of the risk associated with HPV18 for
cervical cancer compared to CIN2/3 obtained in this study is rather
high (ORMH 9.7; 95% CI: 2.4–39). To calculate approximately how
robust this finding is against underdetection of HPV18-associated
lesions by cytology in a cervical screening programme (Woodman
et al, 2003), we estimated the prevalence difference of HPV18
between CIN2/3 and SCC using a sensitivity analysis. We found
that the difference in HPV18 prevalence between CIN2/3 and SCC
still remains statistically significant, even if the detection of
HPV18-associated CIN2/3 lesions through screening compared
to HPV18-positive SCC cases is underestimated by a factor 2.
Underrepresentation of HPV18-associated lesions might be
explained by the finding that HPV18 infections often occur high
in the endocervical canal where lesions are less accessible to
screening. Nevertheless, whether the observed association between
HPV18 and SCC is mainly caused by a preferential risk of HPV18
for the development if SCC, or by underdetection of HPV18
precursor lesions, our findings have important implications for
evaluations of screening programmes. Currently, most, if not all,
screening programmes use CIN2/3 as an intermediate end point
for cervical cancer to evaluate screening efficacy. This approach
seriously underestimates the contribution of HPV18 to the
development of SCC. As a consequence, vaccination to HPV16
and HPV18 will decrease HPV18-associated carcinoma incidence
more than short-term studies using CIN2/3 as an outcome measure
indicate.
In conclusion, HPV18 prevalence is high in invasive SCC
compared to CIN2/3 lesions. Thus, when CIN2/3 is used as
intermediate end point for cervical cancer, the contribution of
HPV18 to the development of invasive SCC is underestimated. As
the vast majority of both SCC and adenocarcinomas is attributable
to HPV16 and HPV18, women with screen-detected HPV16 and
HPV18 infections should be offered more intensive follow-up
schemes compared to women infected with other high-risk HPV
types.
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